Dapagliflozin for kidney protection in type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medication called dapagliflozin (often used in type 2 diabetes) to see if it can help protect the kidneys in people with type 1 diabetes who already have some signs of kidney damage. If it works, it could slow down further kidney decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have had type 1 diabetes for at least 6 months.
- Your urine shows a moderate amount of protein (albumin), which can be a sign of kidney stress.
- Your kidney function (eGFR) is between 30 and 90, indicating mild to moderate kidney problems.
- You are comfortable managing your insulin, including adjusting doses for meals and checking your blood sugar regularly.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily medication can slow down kidney damage in people with type 1 diabetes who already have some kidney problems. It may help protect your kidneys from getting worse.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
This study tests a medication called dapagliflozin, which is usually for type 2 diabetes, to see if it can be used safely in people with type 1 diabetes. It focuses on preventing a serious side effect called ketoacidosis, where the blood becomes too acidic.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
Hear when a new Type 1 Diabetes Mellitus With Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.